^
Association details:
| Biomarker: | VTCN1 underexpression |
|---|---|
| Cancer: | Triple Negative Breast Cancer |
| Drug: | puxitatug samrotecan (AZD8205) (Topoisomerase I inhibitor, B7-H4-targeted antibody-drug conjugate) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
2947 / 25 - Preclinical evaluation of a novel B7-H4 targeted antibody-drug conjugate AZD8205 as a single agent and in combination with novel PARP inhibitor and checkpoint blockade
Published date:
03/15/2023
Excerpt:
A single IV administration of AZD8205 at 3.5 mg/kg provided robust antitumor activity in patient-derived xenografts from TNBC, ovarian and cholangiocarcinoma tumors, with overall response rates in B7H4-expressing samples of 75%, 64% and 21% respectively....Therapeutic benefit of combining AZD8205 with checkpoint immunotherapies was then evaluated in syngeneic models, demonstrating enhanced antitumor efficacy of AZD8205 when combined with an anti-PD-L1 antibody. These data demonstrate that AZD8205 is a promising therapeutic candidate for the treatment of B7-H4 positive solid tumors.
